SEC Form 4 · accession 0001437749-18-021034
BioCardia, Inc. · BCDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Altman
Officer — President and CEO · Director
Period of report
Nov 14, 2018
Accepted (ET)
Nov 16, 2018 · 8:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000925741
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 14, 2018 | P | 2,500 | $2.224 | A | 725,892 | D | |
| Common StockF2 | Nov 15, 2018 | P | 2,500 | $2.4286 | A | 728,392 | D | |
| Common StockF3 | Nov 16, 2018 | P | 1,400 | $2.3946 | A | 729,792 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $2.05 to $2.50 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price.
- F2This transaction was executed in multiple trades at prices ranging from $2.355 to $2.45 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price.
- F3This transaction was executed in multiple trades at prices ranging from $2.325 to $2.40 per share. The price reported above reflects the weighted average per share purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares purchased at each separate price.